Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

AN8025

Other · developed by Adlai Nortye Biopharma Co.

Phase 1 Most advanced trial

ANL Developer

1 Registered trials

What is AN8025?

AN8025 is an investigational agent being studied for advanced or metastatic solid tumors, including PD(L)-1 refractory advanced solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Other
Therapy area: Oncology
Developer: Adlai Nortye Biopharma Co., Ltd. (ANL)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07639047	Phase 1	Advanced Solid Tumor (Phase 1)	Recruiting	ANL

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Solid Tumor (Phase 1)

More from Adlai Nortye Biopharma Co.

AN4005 Phase 1 AN4035 Phase 1 AN9025 Phase 1 Palupiprant Phase 1

Sources

ClinicalTrials.gov NCT07639047

Updated Oct 11, 2026. Something wrong or missing? Report it on the ANL page.

Follow ANL, the company behind AN8025

See ANL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ANL catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z